The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas

SELEK A., Cetinarslan B., CANTÜRK Z., Tarkun I., HANAZAY Y., VURAL Ç., ...Daha Fazla

GROWTH HORMONE & IGF RESEARCH, cilt.45, ss.1-5, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.ghir.2019.01.001
  • Dergi Adı: GROWTH HORMONE & IGF RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1-5
  • Anahtar Kelimeler: Somatostatin analogue, Ki-67, GH-secreting adenomas, Acromegaly, PREOPERATIVE OCTREOTIDE TREATMENT, TUMOR VOLUME, EXPRESSION, APOPTOSIS, CONSENSUS, CRITERIA, THERAPY, MARKER
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Purpose: Somatostatin analogues (SSAs) can slow down the growth of neuroendocrine tumors. However, the mechanism remains unclear. Recent studies on patients with acromegaly suggest that SSAs may induce apoptosis, increase autophagy, and decrease cell proliferation of pituitary adenoma. Ki-67-labeling index is a marker of cellular proliferation; therefore, decreased levels are associated with inhibition of proliferation. The aim of this study was to evaluate and compare the Ki-67-labeling index of GH-secreting pituitary adenoma tissues in patients who had undergone pituitary surgery twice due to residual or recurrent tumors and had received SSA treatment between the two surgeries.